Stronger Together: Neurolex develops a “vocal biomarker” to rapidly screen for COVID-19

David Smith
Jun 16 · 1 min read

CEO Jim Schwoebel founded Neurolex after his brother experienced a psychotic episode, and he noticed that his brother’s voice changed. The Boston-based company has developed “vocal biomarkers” to detect mental health issues, and with the advent of the coronavirus pandemic is working to adapt the technology to identify COVID-19 symptoms using only a voice recording.

In this interview, hear the story behind vocal biomarkers, and how Neurolex has scaled to meet 10x demand under stringent security and compliance requirements during the COVID-19 pandemic.

If you’d like to conduct your own voice survey, take a look at SurveyLex, the Neurolex product that is being used to collect data for the vocal biomarkers.

This interview is part of the Stronger Together series. Click here for more interviews and additional resources for startups.

Welcome to a place where words matter. On Medium, smart voices and original ideas take center stage - with no ads in sight. Watch

Follow all the topics you care about, and we’ll deliver the best stories for you to your homepage and inbox. Explore

Get unlimited access to the best stories on Medium — and support writers while you’re at it. Just $5/month. Upgrade

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store